Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Jifang Gong, MD
- Phone Number: 008601088196561
- Email: goodjf@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100032
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Ji Jiang
-
Beijing, Beijing, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Jifang Gong
- Phone Number: 00861088196561
- Email: goodjf@163.com
-
Beijing, Beijing, China, 100142
- Not yet recruiting
- No.52 Fucheng Road, Haidian District,Beijing,
-
Principal Investigator:
- Lin Shen
-
Contact:
- Jifang Gong
- Phone Number: 008601088196561
- Email: goodjf@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patient willing to sign an Investigational Review Board(IRB) approved written informed consent document
- patient age: 18 years -75years
- patient must have histologically confirmed solid tumor
- patient must have uncurable and unresectable solid tumor of advanced stages
- patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- patient must have a life expectancy at least 12 weeks
- patient must have at least one lesion measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0
- patient must have progress or recurrence after at least one chemotherapy regimen for advanced stage
- patient must have adequate marrow,hepatic and renal function: defined as ANC≥2.0 × 109/L,PLT ≥10 ×109/dL, Hb ≥ 9g/dL;GOT/GPT≤2.5×ULN;Toltle bilirubin ≤1.5×ULN; Serum creatinine ≤1.5×ULN or Creatinine clearance≥40ml/min(according to Cockcroft-Gault;
- patient must have the left ventricular ejection fraction (LVEF)≥50% confirmed by ultrasonic heart scanning
- women must have the negative pregnancy test; women and men must agree to use adequate contraception
Exclusion Criteria:
- patient must non have received any other antitumor therapy, including chemotherapy, radiotherapy, hormonal therapy, biological therapy, immunotherapy and any other investigational agent within 4 weeks prior to starting study
- patient must non have any pre-existing toxity from prior antitumor therapy (any≥ grade 2, any≥1 peripheral neuropathy, excluding alopecia)
- patient must non have uncontrolled cerebral metastases
- patient must non have any uncontrolled heart illness including, but not limited to, ongoing symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, arterial hypertension (≥180/110), heart failure and myocardial infarction within 6 months prior to starting study
- Patient must not have a history of a malignancy tumor except for the following: adequately treated localized basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix for at least 5 years
- patient must non have any serious illness including, but not limited to hepatic, renal, respiratory and uncontrolled diabetes mellitus
- patient must non have psychiatric illness/social situations that would limit compliance with study requirements.
- patient must non have active or uncontrolled infection including, but not limited to tuberculosis,HIV,HBV, HCV
- Patient must non be receiving any other antitumor agent
- patient must non be pregnant and/or breastfeeding
- patient must non be receiving protease inhibitors,inhibitors of CYP3A4,antifungal agents and inducing agent of CYP3A4
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose level A
Paclitaxel liposome injection 135mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
|
Other Names:
|
|
Experimental: Dose level B
Paclitaxel liposome injection 175mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
|
Other Names:
|
|
Experimental: Dose level C
Paclitaxel liposome injection 210mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
|
Other Names:
|
|
Experimental: Dose level D
Paclitaxel liposome injection 250mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
|
Other Names:
|
|
Experimental: Dose level E
Paclitaxel liposome injection 300mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
|
Other Names:
|
|
Active Comparator: Comparator
Paclitaxel injection 175mg/m2 on day 1, each 21 days
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum tolerated dose(MTD)of paclitaxel liposome injection
Time Frame: completion of cycle 1(28 days)
|
Graded and described using National Cancer Institute(NCI)Common Terminology Criteria for adverse events (CTCAE 4.0)
|
completion of cycle 1(28 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
dose-limiting toxicities(DLTs) of paclitaxel liposome injection
Time Frame: completion of cycle 1 (28 days)
|
Graded and described using National Cancer Institute(NCI)Common Terminology Criteria for adverse events (CTCAE 4.0)
|
completion of cycle 1 (28 days)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetic characters of paclitaxel liposome injection compared with paclitaxel injection
Time Frame: 0,during infusion 1.5h, 3h, after infusion 15min, 30min, 1h,2h,4h,8h,12h,24h,36h,48h,72 h
|
Peak Plasma Concentration(Cmax), peak time (Tmax), Half life(T1/2), Area under the plasma concentration versus time curve(AUC0-t), Clearance (CL/F), Apparent volume of distribution(Vd/F), Mean Residence Time (MRT),
|
0,during infusion 1.5h, 3h, after infusion 15min, 30min, 1h,2h,4h,8h,12h,24h,36h,48h,72 h
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NJLYSK-LPS-2013-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.